Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Acquires 17,240 Shares of Stock

Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Guillermo Torre acquired 17,240 shares of the company’s stock in a transaction on Thursday, December 26th. The stock was acquired at an average cost of C$1.81 per share, with a total value of C$31,277.77.

Cardiol Therapeutics Trading Up 4.4 %

CRDL opened at C$1.89 on Friday. The stock has a 50-day moving average of C$2.29 and a 200 day moving average of C$2.64. The company has a current ratio of 2.39, a quick ratio of 6.84 and a debt-to-equity ratio of 1.07. Cardiol Therapeutics Inc. has a 12 month low of C$1.09 and a 12 month high of C$4.26. The firm has a market cap of C$132.07 million, a P/E ratio of -4.30 and a beta of 0.70.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.